|
||
|
Press ReleaseAccuro Biologics Ltd announces successful completion of research programme with AC Immune SAABERDEEN, UK -- May 3, 2007 -- Accuro Biologics Ltd, a privately held biotechnology services company, announces the successful completion of all work packages conducted under a Research Agreement with the Swiss biotech company AC Immune SA. Under the agreement initiated in January 2006, Accuro provided antibody engineering and expression clone development services to AC Immune. "We are delighted to have been able to contribute to one of AC Immune's lead programs. The successful completion of the work under this collaboration further demonstrates our ability to deliver on our commitment to high quality research and our client centred approach to collaboration" said Graham Carter, Managing Director of Accuro Biologics. "The team at Accuro Biologics proved themselves to be a technically proficient and highly dependable collaborator. Their strong performance helped AC Immune to efficiently develop their conformation-specific antibody against Alzheimer's Disease and to achieve a major project milestone and business objective" said Prof. Andrea Pfeifer, CEO of AC Immune SA. About Accuro Biologics LtdAccuro Biologics is a specialist research services company to the pharmaceutical, biotechnology and wider research community. The company provides an outsourcing option for those requiring expert services in protein and antibody engineering, cell line development and immunogenicity (T cell epitope) profiling. Founded on a significant industry track record, the company delivers highly cost effective services with added value provided by adherence to time lines, budget and high quality science. The company is UK-based and operates from its own fully equipped laboratories within the Aberdeen Science and Technology Park, Aberdeen, Scotland. For more information, please contact: Graham Carter About AC Immune SAAC Immune is a privately held company focusing on the development of therapies against Alzheimer's disease a so-called conformational disease. AC Immune is using its proprietary immunology platform to develop active and passive immunotherapies against Alzheimer's disease. AC Immune's proprietary immunology platform technology brings the ability to generate conformation-sensitive antibodies for passive and active immune therapies. The company's products are in the preclinical stage and the first product will enter clinical Phase I in 2007. The company was founded in February 2003 in Basel, Switzerland and is located in the Science Park, PSE, on the Campus of the Swiss Federal Institute of Technology in Ecublens.Lausanne, Switzerland. For further information please visit: Return to Press Releases |
||
Printer Friendly